[EN] 1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS<br/>[FR] COMPOSÉS 1,2-DITHIOLANE UTILES DANS LA NEUROPROTECTION, LES MALADIES ET LES ÉTATS AUTO-IMMUNS ET CANCÉREUX
申请人:SABILA BIOSCIENCES LLC
公开号:WO2018049127A1
公开(公告)日:2018-03-15
This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor signaling pathway kinases-mediated diseases; or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3 -ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROSI; MAPK pathway kinases selected from ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, and MEK7; and P13K/AKT/mTor pathway kinases: selected from mTor, P13K a, Ρ13Κ β, P13Kγ, and P13K δ.
这项发明提供了公式(I)的混合物:其中Y1、Y2、Z、X1、X2和W在规范中定义。这些化合物在治疗酪氨酸激酶、MAPK信号通路激酶和Ρ13K/ΑΚΤ/mTor信号通路激酶介导的疾病;或病况中有用,如神经退行性疾病、神经保护、癌症、自身免疫以及与选择自FYN、FYN Y531F、FLT3、FLT3-ITD、BRK、ITK、FRK、BTK、BMX、SRC、FGR、YES1、LCK、HCK、RET、CSK、LYN和ROSI的酪氨酸激酶调节相关的其他疾病和病况;从ARAF、BRAE CRAP、ERK1/2、MEK1、MEK2、MEK3、MEK4、MEK5、MEK6和MEK7中选择的MAPK通路激酶;以及P13K/AKT/mTor通路激酶:从mTor、P13Kα、Ρ13Κβ、P13Kγ和P13Kδ中选择。